Literature DB >> 6881138

Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease.

P G Pentchev, B Neumeyer, L Svennerholm, C G Groth, R O Brady.   

Abstract

The enzymatic activity of glucocerebrosidase in splenic extracts of the adult nonneurological form of Gaucher disease (type I) was 15% +/- 7% of normal, and the titer of enzyme cross-reacting material (ECRM) in these spleens was 54% +/- 9% of normal. The titer of ECRM in splenic extracts of tissues obtained from patients with the neurological forms of Gaucher disease (types II and III) was essentially the same as in type I Gaucher spleens (59% +/- 10% of normal), but the measurable catalytic activity of glucocerebrosidase in these spleens was substantially lower than that found in type I Gaucher spleens (2.3% +/- 0.6% of normal). Thus, the attentuated glucocerebrosidase activity in spleens from all three forms of Gaucher disease appears to stem from a structurally mutated enzyme that is altered in its catalytic efficiency and possibly in its antigenic expression.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6881138      PMCID: PMC1685741     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  8 in total

1.  Glucocerebrosidase from human placenta.

Authors:  F S Furbish; H E Blair; J Shiloach; P G Pentchev; R O Brady
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

2.  Gaucher disease: isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue.

Authors:  P G Pentchev; R O Brady; H E Blair; D E Britton; S H Sorrell
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

3.  Isolation and characterization of glucocerebrosidase from human placental tissue.

Authors:  P G Pentchev; R O Brady; S R Hibbert; A E Gal; D Shapiro
Journal:  J Biol Chem       Date:  1973-08-10       Impact factor: 5.157

4.  Identification of heterozygous carriers of lipid storage diseases. Current status and clinical applications.

Authors:  R O Brady; W G Johnson; B W Uhlendorf
Journal:  Am J Med       Date:  1971-10       Impact factor: 4.965

5.  The isolation and characterization of sphingomyelinase from human placental tissue.

Authors:  P G Pentchev; R O Brady; A E Gal; S R Hibbert
Journal:  Biochim Biophys Acta       Date:  1977-08-24

6.  A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase.

Authors:  P G Pentchev; A E Gal; A D Booth; F Omodeo-Sale; J Fouks; B A Neumeyer; J M Quirk; G Dawson; R O Brady
Journal:  Biochim Biophys Acta       Date:  1980-09-08

7.  Quantitative immunoassay of adenosine deaminase in combined immunodeficiency disease.

Authors:  D A Carson; R Goldblum; J E Seegmiller
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

8.  Radioimmunochemical quantitation of human adenosine deaminase.

Authors:  P E Daddona; M A Frohman; W N Kelley
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

  8 in total
  9 in total

1.  Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

Authors:  J M Aerts; W E Donker-Koopman; S Brul; S Van Weely; M C Sa Miranda; J A Barranger; J M Tager; A W Schram
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

2.  Human acid beta-glucosidase: Northern blot and S1 nuclease analysis of mRNA from HeLa cells and normal and Gaucher disease fibroblasts.

Authors:  P N Graves; G A Grabowski; M D Ludman; P Palese; F I Smith
Journal:  Am J Hum Genet       Date:  1986-12       Impact factor: 11.025

3.  Crocus transcription factors CstMYB1 and CstMYB1R2 modulate apocarotenoid metabolism by regulating carotenogenic genes.

Authors:  Zahid Yaqoob Bhat; Tabasum Mohiuddin; Amit Kumar; Alberto José López-Jiménez; Nasheeman Ashraf
Journal:  Plant Mol Biol       Date:  2021-08-21       Impact factor: 4.076

4.  Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.

Authors:  D Fabbro; R J Desnick; G A Grabowski
Journal:  Am J Hum Genet       Date:  1987-01       Impact factor: 11.025

5.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

Authors:  G A Grabowski; T Dinur; K M Osiecki; J R Kruse; G Legler; S Gatt
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

6.  Gaucher disease (type 1): physical and kinetic properties of liposomal and soluble 'acid' beta-glucosidase.

Authors:  M Carroll
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

7.  Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.

Authors:  J E Bergmann; G A Grabowski
Journal:  Am J Hum Genet       Date:  1989-05       Impact factor: 11.025

8.  Cross-reacting material in Gaucher disease fibroblasts.

Authors:  E Beutler; W Kuhl; J Sorge
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

9.  Gaucher Disease and Gaucher Cells.

Authors:  Sevgi Gözdaşoğlu
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.